AI-POWERED
RWD-DRIVEN
PATIENT FINDING

Let's Connect

Market Assessment

Confirm the Target Patient Population Warrants Research and Development Efforts

Who is my target patient population? What is their diagnostic and treatment journey? How large is the market for my candidate or expanded-use therapy?

Clinical Study Recruitment

Develop Effective Therapeutic Intervention and Drive Timely Approval

Who are my medically eligible patients to recruit for study? Around which sites do these patient clusters exist? Which HCPs and KOLs are most engaged?

Clinical Study Recruitment

Develop Effective Therapeutic Intervention and Drive Timely Approval

Commercial Effectiveness

Optimize Product Launch and Peak Sales Attainment

How do we focus on the highest value patient targets and maximize engagement channels with HCPs for disease interception and therapy education?

Define, Find and Profile the Ideal Patient

Whether seeking to discover patients yet to be diagnosed, ready to progress to a second or third line therapy or at risk of non-adherence, we isolate the ideal patient population, leveraging ML/AI to predict a lookalike audience at scale and its associated health care providers via modeling techniques.

Map Their Diagnostic and Treatment Journey

We examine signals across the continuum of care to address questions related to patient experience (e.g., demographics, comorbidities, symptomatology and treatment) and health care provider dynamics (e.g., key treaters, specialty inference and payers) to provide high-definition guidance.

Map Their Diagnostic and Treatment Journey

Uncover and Engage Their Healthcare Ecosystem

While the industry has historically used field observation, primary research and secondary data to understand health care provider dynamics, we place the patient at the center of all analysis and precisely map treating physicians, referral networks and key opinion leaders for a high-definition view.

Define, Find and Profile the Ideal Patient

Map Their Diagnostic and Treatment Journey

Uncover and Engage Their Healthcare Ecosystem

0+

IPM.ai projected the existence of ~800 to 2,400 undiagnosed patients for a client treating a rare disease with only 100 documented cases.

0%

IPM.ai helped a client with a therapy for an ultra-rare life-threatening disease (<6,500 patients in the US) increase the diagnosis rate by 40%.

0

IPM.ai found ~10,000 patients who would benefit from a client’s first-in-class therapy for a rare condition and ~4,000 HCPs treating likely patients.

0

IPM.ai found ~400 patients for a client’s treatment of a rare muscular disorder that lacked an ICD-10 classification for effective diagnosis.

0%

IPM.ai delivered a database with 13,000 top-decile HCPs accounting for 60% of total patient volume to a client with a first-in-market treatment.

0

IPM.ai found ~7,000 HCPs treating hidden patients for a disease with less than 2,000 patients, raising the positive-patient ID rate.

0X

IPM.ai projected the existence of ~800 to 2,400 undiagnosed patients for a client treating a rare disease with only 100 documented cases.

0%

IPM.ai helped a client with a therapy for an ultra-rare life-threatening disease (<6,500 patients in the US) increase the diagnosis rate by 40%.

0

IPM.ai found ~10,000 patients who would benefit from a client’s first-in-class therapy for a rare condition and ~4,000 HCPs treating likely patients.

0

IPM.ai found ~400 patients for a client’s treatment of a rare muscular disorder that lacked an ICD-10 classification for effective diagnosis.

0%

IPM.ai delivered a database with 13,000 top-decile HCPs accounting for 60% of total patient volume to a client with a first-in-market treatment.

0

IPM.ai found ~7,000 HCPs treating hidden patients for a disease with less than 2,000 patients, raising the positive-patient ID rate.

Significantly Improving Patient Outcomes

By shrinking the diagnostic odyssey and driving earlier therapeutic intervention.

Guiding Time-Sensitive and Critical Business Decisions

That accelerate the commercialization of critical therapies, quicker with less risk.

Reducing Healthcare Friction and Costs

Through earlier disease interception and minimization of non and misdiagnosis.

Significantly Improving Patient Outcomes

By shrinking the diagnostic odyssey and driving earlier therapeutic intervention.

Guiding Time-Sensitive and Critical Business Decisions

That accelerate the commercialization of critical therapies, quicker with less risk.